Kidney Cancer Clinical Trial

Clinical Trial Finder Kidney Cancer Trials

Enzalutamide Before Surgery in Treating Patients With Kidney Cancer

See Locations Near You

Summary

This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are a type of hormone produced by the body that may cause kidney tumors to grow. Anti-hormone therapy, such as enzalutamide, may lessen the amount of androgens produced by the body and keep kidney tumors from growing.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. To investigate the effects of neoadjuvant enzalutamide on clear cell renal cell carcinoma (ccRCC).

OUTLINE:

Patients receive enzalutamide orally (PO) daily for 90 days in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy.

After completion of study treatment, patients are followed up every 3 months.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Clinical T1N0M0 (=< 7 cm) renal mass as measured on cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI])
Biopsy proven ccRCC
Tumor with androgen receptor (AR) expressed >= 4580 copies/ug ribonucleic acid (RNA)
Can provide informed consent
Adequate hepatic function (>= 1.5 x upper limit of normal [ULN]; patient's with Gilbert's disease are not excluded)
Adequate renal function (estimated glomerular filtration rate [GFR] > 40mL/min)
No evidence of metastatic disease on baseline imaging (chest x-ray [CXR] or chest CT, abdominal CT or MRI)
Eastern Cooperative Oncology Group (ECOG) performance status =< 2

Exclusion Criteria:

Prior use of androgen deprivation including enzalutamide
Pregnant women or women who are of child bearing age who are not willing to use two (2) forms of contraception during treatment with enzalutamide and for six (6) months after treatment
Men must use adequate methods of contraception during and at least 3 months after treatment if engaging in sexual activity with a female of child bearing age
Known hypersensitivity to enzalutamide
History of unprovoked deep vein thrombosis/pulmonary embolism (DVT/PE) in past twelve (12) months
Inability to stop anticoagulants/antiplatelet therapy peri-operatively
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma)
History of loss of consciousness or transient ischemic attack within twelve (12) months of enrollment
Any unstable, serious co-existing medical conditions including but not limited to myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within twelve (12) months prior to screening
Known or suspected brain metastasis or active leptomeningeal disease
Current use of exogenous testosterone
Retroperitoneal/hilar adenopathy concerning for locally advanced disease
Metastatic RCC

Study is for people with:

Kidney Cancer

Phase:

Early Phase 1

Estimated Enrollment:

3

Study ID:

NCT02885649

Recruitment Status:

Terminated

Sponsor:

Rutgers, The State University of New Jersey

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Rutgers Cancer Institute of New Jersey
New Brunswick New Jersey, 08903, United States

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Early Phase 1

Estimated Enrollment:

3

Study ID:

NCT02885649

Recruitment Status:

Terminated

Sponsor:


Rutgers, The State University of New Jersey

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider